TARA (Protara Therapeutics) Forward P/E Multiple
Protara Therapeutics is developing a comprehensive environment to combat oncology and rare pathologies, creating unique approaches to the therapy of lymphatic disorders. This price chart demonstrates the Forward P/E, which currently stands at 0.00. The company is also testing targeted drugs against bladder cancer, leveraging its orphan drug developer status to minimize market pressure.
Summary analytical data breakdowns for Protara Tx (TARA)
- current price and projected stock value:
- business market valuation indicators:
- book capitalization information:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Protara Therapeutics|TARA - Long-Term Liabilities to Capital|Short-Term Debt to Equity Protara Therapeutics|TARA - Company Aggregate Indebtedness|Debt to Book Capitalization Ratio Protara Therapeutics Inc|TARA - Company Long-Term Loans and Borrowings|Company Short-Term Debt Protara Therapeutics|Quick Liquidity Indicator protaratx.com
- financial results and valuation multiples details:
TARA - Profit After Payment of Taxes|Projected Future Earnings Protara Therapeutics|TARA - P/E Multiple|Future Price to Earnings Protara|TARA - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Protara Therapeutics Inc|TARA - Operating profit EBITDA|Net earnings per share for the last 12 months Protara Therapeutics|TARA - Earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months protaratx.com|TARA - Net earnings per one share growth for the current year|Earnings growth forecast for next year Protara Therapeutics
- sales volume and revenue indicators:
Fundamental company valuation:TARA Protara Therapeutics, Inc.
Protara Therapeutics develops innovative drugs for the therapy of orphan oncological diseases. By analyzing the company's forward P/E ratio, an investor can see the relationship between the current quote and projected net income. This metric objectively measures market expectations regarding the monetization of scientific research and the costs of RSU packages for scientists. The indicator's trend allows for an assessment of the degree of business overvaluation. This tool is critically important for calculating the fundamental risks of a biopharmaceutical asset.
Direct competitors
Projected Price to Earnings ONC (BeiGene)|HALO (Halozyme Therapeutics, Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple RVMD (RevMed)|AAPG - Projected Price to Earnings|CGON: Projected Price to Earnings|URGN - Forward P/E Multiple|Bicara Therapeutics (BCAX) - Future Price to Earnings|Personalis Inc - Future Price to Earnings Multiple|ERAS (Erasca Corp) - Forward P/E Multiple|Projected Price to Earnings Ratio Delcath Corp DCTH|Future Price to Earnings Y-mAbs Therapeutics (YMAB)|AURA: Price to Expected Earnings Ratio|Future Price to Earnings Candel Therapeutics, Inc. CADL|Future Price to Earnings Multiple ARAY|SLS - Future Price to Earnings|Projected Price to Earnings Ratio Actuate Therapeutics Inc|CTOR (Citius Oncology, Inc.) - Projected Price to Earnings|HURA: Market Cap to Future Earnings Ratio|FATE (Fate Therapeutics) - Forward P/E Multiple|Forward P/E Multiple Aadi Bio|Future Price to Earnings TScan Therapeutics (TCRX)|CSBR (championsoncology.com) - Future Price to Earnings Multiple|Forward P/E Multiple XBIT (XBiotech)|Forward P/E Multiple CEL-SCI Corp. CVM|OSTX: Projected Price to Earnings|Future Price to Earnings Multiple RADX (radiopharmtheranostics.com)|ARTV (artivabio.com) - Projected Price to Earnings|ANL: Market Cap to Future Earnings Ratio|VERU (Veru Inc.) - Forward P/E Multiple|TPST: Future Price to Earnings Multiple|Forward P/E Multiple XLO|RENB - Projected Price to Earnings Ratio|Future Price to Earnings Mural Oncology MURA|Future Price to Earnings Multiple KAPA|OnKure - Forward P/E Multiple|GDTC - Forward P/E Multiple|curis.com (CRIS) - Future Price to Earnings|Price to Expected Earnings Ratio APLM (Apollomics)|THAR (Tharimmune Corp) - Forward P/E Multiple|Projected Price to Earnings Ratio Advanced Biomed Corp ADVB|Projected Price to Earnings GNPX (Genprex, Inc.)|Forward P/E Multiple calidibio.com (CLDI)|Sunshine Biopharma, Inc. - Projected Price to Earnings|Market Cap to Future Earnings Ratio XBIO (Xenetic Biosciences Inc.)|Salarius - Forward P/E Multiple|Market Cap to Projected Earnings Kitov Pharma PPBT|AONC: Forward P/E Multiple|Projected Price to Earnings beigene.com|Future Price to Earnings Checkpoint Therapeutics, Inc.|elevationoncology.com (ELEV) - Market Cap to Projected Earnings|Projected Price to Earnings ICAD (iCAD, Inc.)|Market Cap to Future Earnings Ratio IKNA|Forward P/E Multiple NTBL (Notable Labs, Ltd.)|Forward P/E Multiple Viracta Therapeutics Inc. VIRX|MOR - Future Price to Earnings|Future Price to Earnings Multiple NAYA (NAYA Biosciences Inc)|AAPGV: Forward P/E Multiple
